Breast Cancer

0:58
TNBC treatment: platinum-based therapy and PARP inhibition
Véronique Dieras
2:59
BROCADE3: veliparib with carboplatin/paclitaxel in HER2-/BRCA+ advanced breast cancer
Véronique Dieras
2:13
HER-2 conversion: a phenomenon in trastuzumab resistance
Russell Petty
1:45
Real-world clinical outcomes in metastatic breast cancer patients treated with palbociclib
Felice Musicco
4:18
IMpower110: atezolizumab vs chemo in PD-L1–selected NSCLC
David Spigel
1:58
Targeted therapy in TNBC
Peter Schmid
4:20
KEYNOTE 522: pembrolizumab as neoadjuvant treatment for early TNBC
Peter Schmid
5:14
Adding alpelisib for HR+/HER2- advanced breast cancer in SOLAR-1: adverse event impacts
Hope Rugo
3:01
BYLieve additional cohort: update on the trial of alpelisib in advanced breast cancer from ESMO
Hope Rugo
10:15
MONALEESA-3 OS results: fulvestrant/ribociclib in postmenopausal HR+/HER2- advanced breast cancer
Dennis Slamon
9:02
Phase 3 KEYNOTE-522 results: pembro/chemo neoadjuvant, pembro adjuvant in early TNBC
Peter Schmid
5:12
MONARCH 2: abemaciclib added to fulvestrant shows OS benefit in HR+/HER2- advanced breast cancer
George Sledge
1:00
IMpassion130: Implications
Peter Schmid
2:30
IMpassion130: immunotherapy for TNBC
Peter Schmid
1:47
TNBC: work to be done
Peter Schmid
4:40
Breast and prostate cancer: maintaining skeletal integrity
Silke Gillessen
vjoncology logo VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJOncology is intended for healthcare professionals